Fast Track

You have full text access to this OnlineOpen article

Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water

  1. Angeline S. Andrew1,2,3,†,*,
  2. Margaret R. Karagas1,3,
  3. Joshua W. Hamilton2,3

Article first published online: 15 JAN 2003

DOI: 10.1002/ijc.10968

Issue

International Journal of Cancer

International Journal of Cancer

Volume 104, Issue 3, pages 263–268, 10 April 2003

Additional Information

How to Cite

Andrew, A. S., Karagas, M. R. and Hamilton, J. W. (2003), Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int. J. Cancer, 104: 263–268. doi: 10.1002/ijc.10968

Author Information

  1. 1

    Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, NH, USA

  2. 2

    Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA

  3. 3

    Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH, USA

  1. †

    Fax: +603-653-0578

*Dartmouth Medical School, 7927 Rubin 462M-3, One Medical Center Drive, Lebanon, NH 03756

Publication History

  1. Issue published online: 4 FEB 2003
  2. Article first published online: 15 JAN 2003
  3. Manuscript Accepted: 19 NOV 2002
  4. Manuscript Revised: 11 OCT 2002
  5. Manuscript Received: 3 JUN 2002

Funded by

  • NIEHS. Grant Number: ES07373
  • NCI. Grant Number: CA57494

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (170K)

REFERENCES

  • 1
    Hartwig A, Groblinghoff UD, Beyersmann D, Natarajan AT, Filon R, Mullenders LH. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis 1997; 18: 399–405.
  • 2
    National Research Council. Arsenic in drinking water. Washington, DC: National Academy Press, 2001.
  • 3
    Karagas MR, Tosteson TD. Assessment of cancer risk and environmental levels of arsenic in New Hampshire. Int J Hygiene Environ Health 2002; 205: 85–94.
  • 4
    Bates MN, Smith AH, Cantor KP. Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol 1995; 141: 523–30.
  • 5
    Araujo FD, Pierce AJ, Stark JM, Jasin M. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002; 21: 4176–80.
  • 6
    Wang X, Peterson CA, Zheng H, Nairn RS, Legerski RJ, Li L. Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand cross-link repair. Mol Cell Biol 2001; 21: 713–20.
  • 7
    Lu G, Cai Q, Zhang W. [ Effects of inorganic arsenicals on the methylation of p16 gene CpG islands and the expression of p16 gene in BEP2D cells]. Zhonghua Yi Xue Za Zhi 2001; 81: 1238–41.
  • 8
    Hamilton JW, Kaltreider RC, Bajenova OV, Ihnat MA, McCaffrey J, Turpie BW, Rowell EE, Oh J, Nemeth MJ, Pesce CA. Molecular basis for effects of carcinogenic heavy metals on inducible gene expression. Environ Health Perspect 1998; 106 (Suppl): 1005–15.
  • 9
    Kaltreider RC, Davis AM, Lariviere JP, Hamilton JW. Arsenic alters the function of the glucocorticoid receptor as a transcription factor. Environ Health Perspect 2001; 109: 245–51.
  • 10
    Kaltreider RC, Pesce CA, Ihnat MA, Lariviere JP, Hamilton JW. Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding. Mol Carcinog 1999; 25: 219–29.
    Direct Link:
  • 11
    Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997; 386: 263–77.
  • 12
    Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997; 94: 10907–12.
  • 13
    Boonchai W, Walsh M, Cummings M, Chenevix-Trench G. Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch Dermatol 2000; 136: 195-8.
  • 14
    Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-κB activation in cultured aortic endothelial cells. Free Radic Biol Med 1996; 21: 783–90.
  • 15
    Roussel RR, Barchowsky A. Arsenic inhibits NF-κB-mediated gene transcription by blocking IκB kinase activity and IκBα phosphorylation and degradation. Arch Biochem Biophys 2000; 377: 204–12.
  • 16
    Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, Dudek EJ. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 1999; 159: 65–75.
  • 17
    Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, Goyer R, Menzer R, Rossman T, Thompson C, Waalkes M. Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect 1999; 107: 593–7.
  • 18
    Chen H, Liu J, Merrick BA, Waalkes MP. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog 2001; 30: 79–87.
    Direct Link:
  • 19
    Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, Greenberg ER. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol 2001; 153: 559–65.
  • 20
    Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect 1998; 106 (Suppl): 1047–50.
  • 21
    Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair and susceptibility to basal cell carcinoma: a case-control study. Am J Epidemiol 1994; 140: 598–607.
  • 22
    Karagas MR, Tosteson TD, Blum J, Klaue B, Weiss JE, Stannard V, Spate V, Morris JS. Measurement of low levels of arsenic exposure: a comparison of water and toenail concentrations. Am J Epidemiol 2000; 152: 84–90.
  • 23
    Agency for Toxic Substances and Disease Registry. Toxicological profile for arsenic. Atlanta: U.S. Department of Health and Human Services, 1999.
  • 24
    Yang JL, Chen MF, Wu CW, Lee TC. Posttreatment with sodium arsenite alters the mutational spectrum induced by ultraviolet light irradiation in Chinese hamster ovary cells. Environ Mol Mutagen 1992; 20: 156–64.
    Direct Link:
  • 25
    Hartmann A, Speit G. Effect of arsenic and cadmium on the persistence of mutagen-induced DNA lesions in human cells. Environ Mol Mutagen 1996; 27: 98–104.
    Direct Link:
  • 26
    Araujo SJ, Wood RD. Protein complexes in nucleotide excision repair. Mutat Res 1999; 435: 23–33.
  • 27
    Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CC. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996; 10: 1219–32.
  • 28
    Li JH, Rossman TG. Inhibition of DNA ligase activity by arsenite: a possible mechanism of its co-mutagenesis. Mol Toxicol 1989; 2: 1–9.
  • 29
    Rountree MR, Bachman KE, Herman JG, Baylin SB. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001; 20: 3156–65.
  • 30
    Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000; 36: 2294–300.
  • 31
    Davis CD, Uthus EO, Finley JW. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J Nutr 2000; 130: 2903–9.
  • 32
    Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 1068–70.
  • 33
    Rossman TG, Uddin AN, Burns FJ, Bosland MC. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol 2001; 176: 64–71.
  • 34
    Pott WA, Benjamin SA, Yang RS. Pharmacokinetics, metabolism, and carcinogenicity of arsenic. Rev Environ Contam Toxicol 2001; 169: 165–214.
  • 35
    Brockmoller J, Cascorbi I, Henning S, Meisel C, Roots I. Molecular genetics of cancer susceptibility. Pharmacology 2000; 61: 212–27.
  • 36
    Thykjaer T, Christensen M, Clark AB, Hansen LR, Kunkel TA, Orntoft TF. Functional analysis of the mismatch repair system in bladder cancer. Br J Cancer 2001; 85: 568–75.
  • 37
    Soliman AS, Bondy ML, Guan Y, El Badawi S, Mokhtar N, Bayomi S, Raouf AA, Ismail S, McPherson RS, Abdel-Hakim TF. Reduced expression of mismatch repair genes in colorectal cancer patients in Egypt. Int J Oncol 1998; 12: 1315–9.
  • 38
    Wei Q, Bondy ML, Mao L, Gaun Y, Cheng L, Cunningham J, Saunders KC, Jiang H, Hong WK, Spitz MR, Strom SS. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 1997; 57: 1673–7.
  • 39
    Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate 2001; 47: 269–75.
    Direct Link:
  • 40
    Wei Q, Eicher SA, Guan Y, Cheng L, Xu J, Young LN et al. Reduced expression of hMLH1 and hGTBP/hMSH6: a risk factor for head and neck cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 309–14.
  • 41
    Cheng L, Guan Y, Li L, Legerski RJ, Einspahr J, Bangert J, Alberts DS, Wei Q. Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 1999; 8: 801–7.
  • 42
    Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996; 66: 779–83.
    Direct Link:
  • 43
    Damia G, Guidi G, D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 1998; 34: 1783–8.
View Full Article (HTML) Get PDF (170K)